Oramed Pharmaceuticals (ORMP) Other Non-Current Liabilities (2011 - 2024)
Oramed Pharmaceuticals' (ORMP) quarterly Other Non-Current Liabilities came in at $60000.0 in Q4 2024, up 445.45% YoY from $11000.0 in Q1 2024, and little changed on a QoQ basis from $60000.0 in Q3 2024.
Oramed Pharmaceuticals (ORMP) Other Non-Current Liabilities (2011 - 2024) Analysis & Trends
Oramed Pharmaceuticals (ORMP) has 14 years of Other Non-Current Liabilities data on file, last reported at $60000.0 in Q4 2024.
- Quarterly Other Non-Current Liabilities rose 445.45% year-over-year to $60000.0 in Q4 2024, while the trailing twelve-month figure through Dec 2024 was $60000.0 (up 445.45% YoY) and the FY2024 annual result came in at $60000.0, up 445.45% from the prior year.
- Other Non-Current Liabilities steadied at $60000.0 in Q4 2024, from $60000.0 in the prior quarter.
- In the past five years, Other Non-Current Liabilities ranged from a high of $6.9 million in Q3 2020 to a low of $11000.0 in Q2 2021.
- A 5-year average of $437000.0 and a median of $62000.0 in 2022 frame the typical range for Other Non-Current Liabilities.
- Annual changes were most pronounced in 2020 — Other Non-Current Liabilities soared 2463.47% — and 2021, when it sank 98.22%.
- Tracing ORMP's Other Non-Current Liabilities over 5 years: stood at $212000.0 in 2020, then plunged by 42.45% to $122000.0 in 2021, then slumped by 50.0% to $61000.0 in 2022, then plunged by 81.97% to $11000.0 in 2023, then soared by 445.45% to $60000.0 in 2024.
- The last three Other Non-Current Liabilities figures came in at $60000.0 (Q4 2024), $60000.0 (Q3 2024), and $60000.0 (Q2 2024), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - |
| 10 | Oramed Pharmaceuticals | 197.61 Mn | 197.61 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2024 | 60,000.00 |
| Sep 30, 2024 | 60,000.00 |
| Jun 30, 2024 | 60,000.00 |
| Mar 31, 2024 | 63,000.00 |
| Dec 31, 2023 | 11,000.00 |
| Sep 30, 2023 | 61,000.00 |
| Jun 30, 2023 | 66,000.00 |
| Mar 31, 2023 | 59,000.00 |
| Dec 31, 2022 | 61,000.00 |
| Sep 30, 2022 | 61,000.00 |
| Jun 30, 2022 | 60,000.00 |
| Mar 31, 2022 | 99,000.00 |
| Nov 30, 2021 | 122,000.00 |
| Aug 31, 2021 | 124,000.00 |
| May 31, 2021 | 11,000.00 |
| Feb 28, 2021 | 177,000.00 |
| Nov 30, 2020 | 212,000.00 |
| Aug 31, 2020 | 6.95 Mn |
| May 31, 2020 | 194,000.00 |
| Feb 29, 2020 | 232,000.00 |